Numerate has developed a proprietary small molecule drug discovery platform combining advances in machine learning, cloud computing, and medicinal chemistry to deliver novel high probability leads. Numerate's platform utilizes the vast amount of available data and cloud computing leveragd by modern machine-learning techniques to discover novel drug candidates. Using the platform, the company has initiated work on several proprietary high-value molecules targeting cardiovascular, metabolic, Alzheimer's, and Huntington's diseases. The company is also partnering with other biopharmaceuticals to find candidates for neurodegeneration, type II diabetes, and infectious diseases.
